Jeffrey Leathe was most recently the Chief Executive Officer and Chairman of the Board at Biocius Life Sciences, a venture backed company involved in developing high throughput instrumentation for mass spectrometry applications in pharmaceutical drug discovery and clinical diagnostic testing. Biocius was acquired by Agilent Technologies in February 2011. Prior to Biocius, Mr. Leathe served as the Senior Vice President and Chief Financial Officer of BioTrove Inc., a venture backed company developing a high throughput PCR platform for use in drug discovery and development. Mr. Leathe was the chief architect of the sale of BioTrove to LIFE Technologies in December 2009.
Before joining BioTrove, Mr. Leathe served as Executive Vice President, Chief Financial Officer and Treasurer for Apogent Technologies from 1990-2003. Apogent, a formerly NYSE-listed global manufacturer of life science research and clinical diagnostic instruments and consumables, was subsequently sold to Fisher Scientific. At Apogent, Jeff managed numerous life science companies around the globe and was a key driver of acquisitions and related public equity and debt financings in excess of $3 billion in the life sciences space.
Jeff is a director and chairman of the audit committee for Bottomline Technologies, a NASDAQ-listed software firm. Jeff received his MBA from the University of North Carolina, Chapel Hill, his B.S. from the University of New Hampshire and holds his CPA.
Gaye joined Excel Venture Management in 2010, and brings more than 15 years of operating experience in business development, new product development, and strategic planning to Excel’s investment process. Previously, Gaye headed up business and commercial development at Microbia, a bio-based chemical company. She also served as Senior Director of Business Development of Synthetic Genomics where she was the first non-founder employee, and as Business Development Manager at Cabot Corporation, a publicly traded materials science company.
Gaye received her M.B.A in Finance and International Management from MIT’s Sloan School and her A.B. from Harvard University.
Peter Kolchinsky, PhD
Dr. Kolchinsky is a founding Partner and Portfolio Manager at RA Capital, a healthcare crossover fund. He is active in both public and private investments in biotechnology areas as diverse as drugs, medical devices, diagnostics, and life science tools. He authored the e-book “The Entrepreneur’s Guide to a Biotech Startup”. He also serves on the board of the American Fertility Association and is a board member of Dicerna [Nasdaq: DRNA] and several private healthcare companies. In the past, Dr. Kolchinsky has served on the Board of Global Science and Technology for the National Academies of Sciences. He received a PhD in Virology from Harvard University. His doctoral work involved studies of the mechanism by which HIV infects cells. He received a Bachelor’s degree from Cornell University.
Andrew G. Raguskus
Andy has over 40 years of experience in delivering high tech products to market, 18 of them in the hearing device industry. He was the Senior Vice President of Operations at ReSound Corporation in the 1990’s and served Sonic Innovations as President and CEO from 1996 to 2005, where he led the company to become one of the medical device industry’s entrepreneurial success stories.
Mr. Raguskus was named “Utah Entrepreneur of the Year” in 2001 by Ernst & Young, CNN, USA Today, and NASDAQ. He began his career designing satellites as a U.S. Air Force officer and was part of the design team for the original CT scanner at General Electric Medical Systems. Currently, Mr. Raguskus is also the CEO of OtoKinetics Inc. a venture backed startup that is developing a fully implantable hearing device similar to a cochlear implant. Mr. Raguskus earned a Bachelor’s Degree in Electrical Engineering from Rensselaer Polytechnic Institute.
Darshana is a Partner at Catalyst Health Ventures, a Healthcare focused venture capital firm. She is a member of Catalyst’s investment committee and actively involved in all aspects of Fund Management including deal origination, management and capital raising. She led Catalyst’’s investments in Augmenix, Lantos Technologies, nVision Medical, Hepregen and Maxwell Health.
Prior to Catalyst, she was an Investigator at Vertex Pharmaceuticals and an integral part of the drug development programs in oncology, metabolic disease, and immunology. Previously she worked at Genome Therapeutics, a Massachusetts-based biotechnology company, at the Dana Farber Cancer Institute and completed an internship at the United Nations. She has authored several publications and scientific journal articles and currently serves as a Catalyst of the Deshpande Center for Technological Innovation at MIT.
Darshana received an MPA from Harvard University, a Master in Cell and Molecular Biology from Boston University, and a BS in Biochemistry from Bombay University in Bombay, India.